- $5.50bn
- $5.67bn
- £361.70m
- 85
- 14
- 94
- 70
2018 June 30th | 2019 June 30th | 2020 June 30th | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 18 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 233 | 260 | 260 | 463 | 362 |
Cost of Revenue | |||||
Gross Profit | 163 | 183 | 180 | 329 | 271 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 164 | 204 | 250 | 439 | 372 |
Operating Profit | 68.8 | 56.1 | 10.5 | 24.4 | -10.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 69.1 | 56.4 | 8.4 | 20.3 | -15.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | 57 | 45.2 | 12.5 | 17.2 | -8.5 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 62.2 | 45 | 12.5 | 17.2 | -8.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 62.2 | 45 | 12.5 | 17.2 | -8.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.409 | 0.346 | 0.237 | 0.25 | 0.228 |
Dividends per Share |